Length 
162 pages 

Date published 
February 2007 

Additional info 
Single-site, country, and global licenses are multi-user, searchable, and cut-and-paste ready PDFs delivered by e-mail.

For Corporate Subscriptions, Multi-Reports Orders, Discounts or Order Questions.  

Contact:
Kerri Kelley
Customer Service
781-972-1347 



Cytokine Therapies and Inhibitors Table of Contents

Cytokine Therapies and Inhibitors: A Vibrant Pipeline and Active Approved Market 

Mark C. Via

CHAPTER 1
BACKGROUND AND SCIENTIFIC OVERVIEW: CYTOKINES ARE INTRACELLULAR MESSENGERS THAT REGULATE THE IMMUNE SYSTEM
1.1. What Are Cytokines?
[SIDEBAR]
The Immune System
1.2. Classification of Cytokines
Interleukins
Interferons
Tumor Necrosis Factors
Transforming Growth Factor-beta
Colony-Stimulating Factors
Chemokines

CHAPTER 2
CYTOKINE THERAPEUTICS: ADMINISTERING CYTOKINES AS DRUGS
2.1. Interleukins
Interleukin-1
Aldesleukin
Denileukin Diftitox
BAY 50-4798
Multikine
IRX-2/IRX-3/IRX-4/IRX-5/IRX-6
EMD 273063/EMD 273066
TG 4010/TG 4001
IL-2 XL
IL-2/EP
Liposomal IL-2
Sangamo BioSciences’ Technology
Others
Interleukin-3
Interleukin-4
PRX321
Interleukin-6
Interleukin-7
IL-7
Interleukin-10
Interleukin-11
Oprelvekin
PEGylated IL-11
Interleukin-12
EGEN-001
AS1409
TDS/IL-12
CYT-41000
Interleukin-13
Cintredekin Besudotox
Uvidem/Collidem
Glioblast-13
Interleukin-18
Iboctadekin
IL-18 Plasmids
Interleukin-21
IL-21
Interleukin-29
IL-29
2.2. Interferons
Interferon a
Intron A/Rebetron/PEG-Intron
Roferon-A/Pegasys
Infergen
Alferon N/Alferon LDO
Multiferon
Albuferon
Oral IFN-a
Topical IFN-a
IFN-a-2b XL
HCV-I.E.T
Locteron/BLX-883
Oroferone
Maxy-alpha
Neoferon
Belerofon
Ambrx’s Enhanced Pegylated IFN-a
Ultra Interferons
PEGylated IFN-a
Interferon beta
Betaferon/Betaseron
Avonex
Rebif
MS-I.E.T.
IFN-beta–Fc
TDS/IFN-beta
Others
Interferon
Actimmune
TG 1042 (Ad-IFN gamma)
Others
Other Interferons
Tauferon
IFN-omega
2.3. Tumor Necrosis Factors
TNF-a
Aurimune (CYT-6091)/AuriTol (CYT-21001)
OncoVEXTNF-a
TRAIL
Rh-Apo2L
Apo2L/TRAIL (AMG 951)
HGS-ETR1/HGS-ETR2/HGS-TR2J
AMG 655
4-1BBL
BMS-663513
GTC Biotherapeutics’ Compound
2.4. Hematopoietic Growth Factors
Erythropoietin
Epoetin a/Aranesp
Epoetin beta/CERA
Epoetin delta
Hematide
FG-2216/FG-4592
GlycoPEG-EPO
EPO-Fc
PT-401
MOD-701
Albupoietin
Repoxygen
Tissue-Protective Cytokines
Granulocyte Colony-Stimulating Factor
Filgrastim /Pegfilgrastim
Lenograstim
Nartograstim
Telintra
AX200
Maxy-G34
GlycoPEG-GCSF
Others
Granulocyte-Macrophage Colony-Stimulating Factor
Sargramostim
Molgramostim
Leucotropin
CTCE-0214/CTCE-0324
Sangamo BioSciences’ Technology
Macrophage Colony-Stimulating Factor
Mirimostim
Stem Cell Factor
Ancestim
Thrombopoietin
AMG 531
Eltrombopag
Thromboplus
c-Mpl Minibody Agonists
2.5. Chemokines
CXCR4

CHAPTER 3
CYTOKINE INHIBITORS: DRUGS THAT BLOCK CYTOKINE ACTIVITY
3.1. Interleukin Inhibitors
Interleukin-1
Anakinra
IL-1 Trap
AMG 108
ACZ885
Interleukin-2
Daclizumab
Basiliximab
MT204
Interleukin-4 and -13
Aerovant/Aeroderm/Aerolast
AMG 317
CAT-354
TNX-650
ISIS 369645
DOM1000P/DOM0910
Zenyth Therapeutics/Merck’s Compounds
Sirna Therapeutics/GlaxoSmithKline’s Compounds
Targepeutics’ Compounds
Interleukin-5
Mepolizumab
BIW-8405
YM-90709
Interleukin-6
Tocilizumab
C326
Interleukin-9
MEDI-528
Interleukin-12 and -23
CNTO 1275
ABT-874
STA-5326
Anti-IL-23 Aptimers
Interleukin-15
AMG 714
CRB-15
Other Interleukins
Centocor Research
ZymoGenetics/Serono/Novo Nordisk Research
3.2. Interferon Inhibitors
Interferon a
MEDI-545/MEDI-546
Interferon gamma
HuZAF
Advanced Biotherapies’ Anti-IFN-gamma Antibodies
3.3. Tumor Necrosis Factor Inhibitors
TNF-a
Etanercept
Infliximab
Adalimumab
Certolizumab Pegol
CNTO 148
CytoFab
CC-10004
ALS-00T2
tgAAC94
XPro 1595
MP8
DOM0200/DOM0100
Ablynx’s Nanobodies
Nastech Pharmaceutical’s Compounds
Devgen’s Compounds
Lymphotoxin-beta
Biogen Idec’s Compounds
BLyS
Belimumab
Atacicept
AMG 623
BR3-Fc
Xencor’s Compound
RANKL
Denosumab
PX 107
Others
CD40L
SGN-40
CHIR 12.12
Biogen Idec/UCB’s Compound
CD30L
MDX-060
SGN-30/SGN-35
XmAb 2513
LIGHT
CoGenesys’s Compound
TWEAK
Biogen Idec’s Research
3.4. Transforming Growth Factor-beta Inhibitors
AP 12009/AP 11014
GC-1008
Anti-TGF-beta2 Aptimers
TGF-beta Receptor Inhibitors
3.5. Colony-Stimulating Factor Inhibitors
G-CSF
Zenyth Therapeutics/MuriGen Therapeutics’ Compounds
GM-CSF
KM002
CAM-3001
MT203
3.6. Chemokine Antagonists
CCR1
MLN3897, MLN3701
PS375179
ChemoCentryx’s Compounds
CCR2
MLN1202
INCB3284/INCB8696
ABN912
CCX915
Telik’s Compound
CCR3
CCR5
Maraviroc
Vicriviroc
PRO 140
INCB9471/INCB15050
HGS004/HGS101
Sangamo BioSciences’ Technology
Others
CCR9
Traficet-EN
CXCR1/ CXCR2
PS291822
656933
PAC-G31P
Others
CXCR3
MDX-1100
AMG 487
CoGenesys’s Compound
CXCR4
Mozobil
AMD070
CTCE-9908
ChemoCentryx’s Compounds
Others
CXCR6
CoGenesys’s Compound
MIF
HMGB
MedImmune/Critical Therapeutics’ Compounds

CHAPTER 4
BUSINESS AND STRATEGIC OUTLOOK: MARKET POTENTIAL FOR CYTOKINE THERAPEUTICS
4.1. The Market for Cytokine-Based Drugs
4.2. Selected Markets
Cancer and Cytopenias
Cancer
Anemia
Neutropenia
Thrombocytopenia
Immune and Inflammatory Diseases
Rheumatoid Arthritis
Crohn’s Disease
Psoriasis
Lupus
Multiple Sclerosis
Asthma
Chronic Obstructive Pulmonary Disease
Infectious Diseases
HIV
Hepatitis C Virus

REFERENCES

GLOSSARY

COMPANY INDEX WITH WEB ADDRESSES